FDA: Higher doses of Xeljanz increase blood clot, death risk in UC

The FDA on Friday issued a safety alert and approved new warnings for the 10-mg, twice-daily dosage of tofacitinib after a possible increased risk for pulmonary embolism and mortality in patients with ulcerative colitis.
Additionally, the FDA alert states that the approved use of tofacitinib (Xeljanz, Pfizer) for UC should be limited to specific patients who are not treated effectively or who experience severe side effects with certain other medicines.
The FDA previously approved tofacitinib for moderate-to-severe UC in 2018.
This new warning approval stemmed from a previous safety alert of

Source link

Related posts

Tools and analytic techniques to synthesise community knowledge in CBPR using computer-mediated participatory system modelling


Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development


Covering the Cover- March 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World